ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2006
Mouse models in oncogenesis and cancer therapy.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Pooled it
- Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research.Journal of experimental & clinical cancer research : CR · 2009Pooled it
- Susceptibility of different mice species to chemical induction of colorectal cancer by 1,2-dimethylhydrazine.Journal of the Egyptian National Cancer Institute · 2025Article
- Mouse Models of Breast Cancer Bone Metastasis.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.Journal of biological engineering · 2024Review
- A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.eLife · 2023Article
- Establishing a three-dimensional scaffold model of hepatoblastoma.Frontiers in bioengineering and biotechnology · 2023Article
- Review
- Identifying drivers of breast cancer metastasis in progressively invasive subpopulations of zebrafish-xenografted MDA-MB-231.Molecular biomedicine · 2022Article
- Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.International journal of molecular sciences · 2021Article
- Development of the FAST-DOSE assay system for high-throughput biodosimetry and radiation triage.Scientific reports · 2020Article
- Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity.Oxidative medicine and cellular longevity · 2020Article
- Genetically Engineered Mouse Models for Liver Cancer.Cancers · 2019Review
- Review
- Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.Breast cancer research : BCR · 2019Article
- In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model.Oncology reports · 2019Article
- RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model.Scientific reports · 2019Article
- 18F-Deoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Monitoring of Dynamic Growth Characteristics of Walker-256 Tumor Models in 3 Different Locations in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Bridging from Brain to Tumor Imaging: (S)-(-)- and (R)-(+)-[Molecules (Basel, Switzerland) · 2018Article
- MicroRNA-886-3P functions as a tumor suppressor in small cell lung cancer.Cancer biology & therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal models have been critical in the study of the molecular mechanisms of cancer and in the development of new antitumor agents; nevertheless, there is still much room for improvement. The relevance of each particular model depends on how close it replicates the histology, physiological effects, biochemical pathways and metastatic pattern observed in the same human tumor type. Metastases are especially important because they are the main determinants of the clinical course of the disease and patient survival, and are the target of systemic therapy. The generation of clinically relevant models using the mouse requires their humanization, since differences exist in transformation and oncogenesis between human and mouse. Although genetically modified (GM) mice have been instrumental in understanding the molecular mechanisms involved in tumor initiation, they have been less successful in replicating advanced cancer. Moreover, a particular genetic alteration frequently leads to different tumor types in human and mouse and to lower metastastatic rates in GM mice than in humans. These findings question the capacity of current GM mouse carcinoma models to predict clinical response to therapy. On the other hand, orthotopic (ORT) xenografts of human tumors, or tumor cell lines, in nude mice reproduce the histology and metastatic pattern of most human tumors at advanced stage. Using ex vivo genetic manipulation of human tumor cells, ORT models can be used to molecularly dissect the metastatic process and to evaluate in vivo tumor response to therapy, using non-invasive procedures. Nevertheless, this approach is not useful in the study of the initial stages of tumorigenesis or the contribution of the immune system in this process. Despite ORT models are more promising than the most commonly used subcutaneous xenografts in preclinical drug development, their capacity to predict clinical response to antitumor agents remains to be studied. Humanizing mouse models of cancer will most likely require the combined use of currently available methodologies.
Indexed as
Identifiers
16760006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.